SEC Comment Letter 0000000000-24-005501 to Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc.
Date: May 14, 2024 · CIK: 0001830214 · Accession: 0000000000-24-005501
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279280
Letter
United States securities and exchange commission logo May 14, 2024 Karen Tepichin, Esq. General Counsel Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Re:Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279280 Dear Karen Tepichin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marko Zatylny, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2024
Karen Tepichin, Esq.
General Counsel
Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
8th Floor
Boston, MA 02210
Re:Ginkgo Bioworks Holdings, Inc.
Registration Statement on Form S-3
Filed May 9, 2024
File No. 333-279280
Dear Karen Tepichin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marko Zatylny, Esq.